Xarelto clinical trials may have been faulty
March 7, 2016
Clinical trials performed by Johnson & Johnson and Bayer pharmaceuticals may have shown the drug Xaralto to be safer than it actually is.
Xaralto is an anti-clotting drug frequently prescribed to prevent strokes in patients with heart disorders. The Food and Drug Administration is investigating whether a faulty blood monitor device used in the clinical trials of the drug skewed testing results.